EXPERIENCE OF APPLICATION OF IPILIMUMAB IN COMBINED THERAPY OF SMALL-CELL LUNG CANCER. ANALYSIS OF DATA OF THE MULTICENTER RANDOMIZED RESEARCH CA 184-156, PHASE III


Cite item

Full Text

Abstract

Patients with advanced small cell lung cancer (SCLC) have an extremely poor prognosis against a background of standard therapy with a combination of etoposide with platinum drugs. In a randomized, double-blind of the CA184-156 phase 3, the efficacy and safety of ipilimumab or placebo in combination with etoposide and platinum preparations was evaluated as the first line treatment for disseminated SCLC. Material and methods. Randomization of patients was carried out in a ratio of 1:1 in the group of therapy: etoposide + platinum drug (carboplatin or cisplatin) + ipilimumab and etoposide + platinum preparation + placebo. Ipilimumab/placebo was administered at a dose of 10 mg/kg every 3 weeks, starting from the 3rd course of chemotherapy to the 6th course of chemotherapy. Further, in the absence of progression, maintenance therapy with ipilimumab/placebo was performed every 12 weeks. The main end point of the study was the assessment of overall survival (OS). Results. Out of 1,132 randomized patients, 954 received at least 1 administration of ipilimumab/placebo in combination with chemotherapy: ipilimumab, n = 478; placebo, n = 476. Median OS was 11.0 months in the chemotherapy group with ipilimumab and 10.9 months, in the chemotherapy group with placebo (RR, 0.94, 95% CI, 0.81-1.09, p =0,3775). The median progression-free survival was 4.6 months in the chemotherapy group with ipilimumab and 4.4 months in the chemotherapy group with placebo. (RR, 0.85, 95% CI, 0.75-0.97). The frequency and severity of side effects in the compared groups was similar, with the exception of diarrhea, rash, and colitis, which occurred significantly more frequent in the chemotherapy group with ipilimumab. The frequency of the discontinuation of therapy due to toxicity was higher in the chemotherapy group with ipilimumab (18% vs. 2%). Treatment-related deaths accounted for 5 in the chemotherapy group with ipilimumab and 2 - in the chemotherapy group with placebo. Conclusion. The addition of ipilimumab to chemotherapy did not contribute to an increase in OS in comparison with only chemotherapy in advanced SCLC patients. Unexpected adverse events in the chemotherapy group with ipilimumab were not noted. The study of the efficacy of ipilimumab in patients with disseminated SCLC in combination with PD1 inhibitors is ongoing. The results obtained in the analysis of data in a subset of 33 patients who participated in this study on the basis of the Department chemotherapy of N.N. Blokhin Russian Cancer Research Center, correspond to data obtained in the entire multicenter study CA184-156.

About the authors

Aleksandr E. Kuzminov

N.N. Blokhin National Medical Research Center of Oncology

Email: alexkouzminov@mail.ru
MD, PhD, Researcher of the Department of Chemotherapy of the Research Institute of Clinical Oncology, Moscow, 115478, Russian Federation Moscow, 115478, Russian Federation

S. G Bagrova

N.N. Blokhin National Medical Research Center of Oncology

Moscow, 115478, Russian Federation

V. A Gorbunova

N.N. Blokhin National Medical Research Center of Oncology

Moscow, 115478, Russian Federation

References

  1. Herbst R.S., Heymach J.V., Lippman S.M. Lung cancer. N. Engl. J. Med. 2008; 359: 1367-80.
  2. van Meerbeeck J.P., Fennell D.A., De Ruysscher D.K. Small-cell lung cancer. Lancet. 2011; 378: 1741-55.
  3. Byers L.A., Rudin C.M. Small cell lung cancer: Where do we go from here? Cancer. 2015; 121: 664-72.
  4. Roth B.J., Johnson D.H., Einhorn L.H. et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: A phase III trial of the Southeastern Cancer Study Group. J. Clin. Oncol. 1992; 10: 282-91.
  5. National Comprehensive Cancer Network: Clinical practice guidelines in oncology: Small cell lung cancer (version 1). https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf
  6. Früh M., De Ruysscher D., Popat S., Crinò L., Peters S., Felip E. Small-cell lung cancer (SCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2013; 24(Suppl 6): vi99-105.
  7. Lebeau B., Chastang C., Allard P., Migueres J., Boita F, Fichet D. et al: Six vs twelve cycles for complete responders to chemotherapy in small cell lung cancer: Definitive results of a randomized clinical trial - The «Petites Cellules» Group. Eur. Respir. J. 1992; 5: 286-90.
  8. Schiller J.H., Adak S., Cella D. et al: Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593-A phase III trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 2001; 19: 2114-22.
  9. Lally B.E., Urbanic J.J., Blackstock A.W. et al. Small cell lung cancer: Have we made any progress over the last 25 years? Oncologist. 2007; 12: 1096-104.
  10. Oze I., Hotta K., Kiura K. et al. Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: Disappointing results. PLoS One. 2009: 4: e7835.
  11. Peifer M., Fern´andez-Cuesta L., Sos M.L. et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat. Genet. 2012; 44: 1104-10.
  12. Darnell R.B. Onconeural antigens and the paraneoplastic neurologic disorders: At the intersection of cancer, immunity, and the brain. Proc. Natl. Acad. Sci. USA. 1996; 93: 4529-36.
  13. Koyama K., Kagamu H., Miura S. et al: Reciprocal CD4+ T-cell balance of effector CD62Llow CD4+ and CD62LhighCD25+ CD4+ regulatory T cells in small cell lung cancer reflects disease stage. Clin. Cancer Res. 2008; 14: 6770-9.
  14. Antonia S.J., Lo´pez-Martin J.A., Bendell J. et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): A multicentre, open-label, phase 1/2 trial. Lancet Oncol. 10.1016/S1470-2045(16)30098-5 [epub ahead of print on June 3, 2016]
  15. Ott P.A., Elez Fernandez M.E., Hiret S. et al. Pembrolizumab for extensive-stage SCLC: Efficacy and relationship with PD-L1 expression. Presented at the 16th World Conference on Lung Cancer, Denver, CO, September 6-9, 2015 (abstr 3285)
  16. Reck M., Bondarenko I., Luft A. et al: Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: Results from a randomized, double-blind, multicenter phase 2 trial. Ann.Oncol. 2013; 24: 75-83.

Copyright (c) 2017 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies